[203 Pages Report] The global aspiration and biopsy needles market is valued at an estimated USD 879 million in 2021 and is projected to reach USD 1,303 million by 2027, at a CAGR of 6.8%. Factors such as the rising prevalence of cancer, initiatives undertaken by government and global health organizations, and the increasing preference for minimally invasive procedures are the major factors driving the growth of the aspiration and biopsy needle market. 

COVID-19 led to a significant drop in imaging procedures since March 2020 (for all modalities). A late resurgence of imaging throughput was observed in the second half of 2020; however, the overall throughput remained at a level of roughly 80% of the baseline volume for the entire year.

In April 2020, the US FDA issued a guidance to provide a policy to help expand the availability and capability of medical X-ray, ultrasound, MRI systems, and image analysis software used to perform needle biopsy while mitigating the circumstances that could lead to the exposure of patients, healthcare providers, and healthcare technology management (HTM) to COVID-19. 

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71036825

Globally, there has been a significant increase in the number of people suffering from cancer. This can be attributed to a number of factors, such as lifestyle changes, unhealthy diets, and increasing tobacco consumption. According to estimates from the International Agency for Research on Cancer (IARC), in 2018, there were 17.0 million new cancer cases and 9.5 million cancer deaths worldwide. By 2040, the global burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths, primarily due to the growth and aging of the population.